Differences between different versions of Opicapone and suggestions for selection

Opicapone is a new, long-acting COMT inhibitor. Its main indication is for patients with moderate to advanced Parkinson's disease who experience "end-dose fluctuations" or "off-period symptoms" worsening when treated with levodopa combined with dopa decarboxylase inhibitors (such as carbidopa or benserazide). By inhibiting the activity of peripheral COMT enzymes, opicapone can reduce the peripheral degradation of levodopa and extend its plasma half-life, thereby increasing central dopamine levels and alleviating fluctuations in motor symptoms. Compared with traditional COMT inhibitors such as Tolcapone or Entacapone, Opicapone has the significant advantage of only needing to be taken once a day and lower risk of liver toxicity. Therefore, it has been recommended as the preferred COMT inhibitor combination drug in overseas Parkinson's disease guidelines.

The versions of Opicapone currently on the market mainly include the European version and the American version, both with the trade name“Ongentys”. The main ingredient and dosage form of the two versions are Opicapone 50mg capsules, and the clinical use standards are basically the same, but the drug packaging, drug instruction language, production batches and regulatory standards are slightly different. In terms of efficacy, there is no significant difference between the two. Patients can choose a suitable version according to the purchasing channel and doctor’s recommendations.

As for generic drugs, there are currently no generic versions of Opicapone approved by international drug regulatory agencies on the market, which means that all available drugs are original drugs. For patients, although the price is not as economical as generic drugs, original drugs are more guaranteed in terms of quality control, clinical safety and effectiveness. When choosing the Opicapone version, priority should be given to channels with clear drug traceability sources, such as regular pharmacies in EU countries, US version prescription channels, or domestic overseas drug purchasing platforms with drug supervision qualifications.

Reference materials:https://www.ongentys.com/